Abstract:Introduction In trials, subgroup analyses are used to examine whether treatment effects differ by important patient characteristics. However, which subgroups are most commonly reported has not been comprehensively described. Design and settings Using a set of trials identified from the US clinical trials register (ClinicalTrials.gov), we describe every reported subgroup for a range of conditions and drug classes. Methods We obtained trial characteristics from ClinicalTrials.gov via the Aggregate Analysis of ClinicalTrials.gov database. We subsequently obtained all corresponding PubMed-indexed papers and screened these for subgroup reporting. Tables and text for reported subgroups were extracted and standardised using Medical Subject Headings and WHO Anatomical Therapeutic Chemical codes. Via logistic and Poisson regression models we identified independent predictors of result reporting (any vs none) and subgroup reporting (any vs none and counts). We then summarised subgroup reporting by index condition and presented all subgroups for all trials via a web-based interactive heatmap (https://ihwph-hehta.shinyapps.io/subgroup_reporting_app/). Results Among 2235 eligible trials, 23% (524 trials) reported subgroups. Follow-up time (OR, 95%CI: 1.13, 1.04–1.24), enrolment (per 10-fold increment, 3.48, 2.25–5.47), trial starting year (1.07, 1.03–1.11) and specific index conditions (eg, hypercholesterolaemia, hypertension, taking asthma as the reference, OR ranged from 0.15 to 10.44), predicted reporting, sponsoring source and number of arms did not. Results were similar on modelling any result reporting (except number of arms, 1.42, 1.15–1.74) and the total number of subgroups. Age (51%), gender (45%), racial group (28%) were the most frequently reported subgroups. Characteristics related to the index condition (severity/duration/types etc) were frequently reported (eg, 69% of myocardial infarction trials reported on its severity/duration/types). However, reporting on comorbidity/frailty (five trials) and mental health (four trials) was rare. Conclusion Other than age, sex, race ethnicity or geographic location and characteristics related to the index condition, information on variation in treatment effects is sparse. PROSPERO registration number CRD42018048202.

Understanding of interaction (subgroup) analysis in clinical trials

Subgroup identification in clinical trials: an overview of available methods and their implementations with R

Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?

Interaction tests with covariate-adaptive randomization

Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors.

Tutorial in biostatistics: data‐driven subgroup identification and analysis in clinical trials

Comparing Approaches to Treatment Effect Estimation for Subgroups in Clinical Trials

Group-by-Treatment Interaction Effects in Comparative Bioavailability Studies

Challenges in interpreting results from ‘multiple regression’ when there is interaction between covariates

How to Use A Subgroup Analysis

Meta-analysis and subgroups

Challenges and Solutions to Pre- and Post-Randomization Subgroup Analyses

Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials

Testing for a treatment effect in a selected subgroup

Subgroup Analyses in Randomised Controlled Trials: Cohort Study on Trial Protocols and Journal Publications.

Description of subgroup reporting in clinical trials of chronic diseases: a meta-epidemiological study

Individual Participant Data Meta‐analysis to Examine Interactions Between Treatment Effect and Participant‐level Covariates: Statistical Recommendations for Conduct and Planning

Characteristics and interpretation of subgroup analyses based on tumour characteristics in randomised trials testing target-specific anticancer drugs: design of a systematic survey

Estimating the treatment effect in a subgroup defined by an early post-baseline biomarker measurement in randomized clinical trials with time-to-event endpoint

Investigating Stability in Subgroup Identification for Stratified Medicine

Evaluating the impact of treating the optimal subgroup